Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

This observational study tracks how well biologic drugs and JAK inhibitors (newer types of arthritis medications that work by blocking inflammatory signals) continue to work over time for people with rheumatoid arthritis in a real-world clinical setting — and what factors predict whether they keep working. **You may be eligible if...** - You are 18 or older and have been diagnosed with rheumatoid arthritis - You have received at least one dose of a biologic drug or JAK inhibitor - You are followed at the Rheumatology Unit of a participating hospital - You have had at least two clinical assessments on record **You may NOT be eligible if...** - Your medical records are missing too much baseline or follow-up data Talk to your doctor to see if this trial is right for you.